PPARγ has also been shown to inhibit tumor angiogenesis and growth of A594 lung cancers in vivo by blocking the production of CXCL1, CXCL5, and interleukin 8, or CXCL8 (CXC chemokines with a specific amino acid sequence of glutamic acid-leucine-arginine (ELR) before the first cysteine of the CXC motif (ELR-positive)). Here, PPARG is linked to neoplasm.